The document discusses how biotechnology has helped reduce breast cancer deaths through the use of Mammaprint. Mammaprint utilizes an understanding of breast cancer evolution and metabolism at the cellular level, biomarkers, and genetic polymorphisms to better determine patient risk and appropriate treatment. Characterizing the metabolic interactions between cancer cells, stromal cells, and immune cells provides insight into tumor progression and treatment resistance that can improve outcomes. Genome studies have identified genetic variants associated with breast cancer risk, and incorporating this genetic data into risk models enhances risk assessment and targeted treatment approaches.